The innovative drugmaker’s newfound profitability marks its transition into a new stage characterized by stability and virtuous development cycles
image credit: Bamboo Works
Key Takeaways:
- InnoCare posted an annual profit of 644 million yuan, driven by licensing and product sales, achieving profitability two years ahead of plan
- The company has made significant strides in global expansion, including an out-licensing agreement with Prolium Bioscience
A confluence of factors, including market liquidity, investor composition, and cross-border capital controls, have led to significant valuation gaps between companies listed in Hong Kong and their concurrent listings on China’s A-share markets in Shanghai and Shenzhen. InnoCare Pharma Ltd. (9969.HK; 688428.SH) offers one such case, as its Hong Kong shares consistently trade at roughly half the valuation of its Shanghai listing. That could present potential upside for the Hong Kong shares, particularly as the company continues to evolve into a more stable business with diverse revenue streams and consistent profits.
InnoCare’s 2025 annual report, released on March 25, included its first full-year profit, coinciding with the company’s 10th anniversary — a milestone signaling its evolution from biotech startup to a mature, independent biopharma player.
Despite attracting strong market attention for its big business development deals, the company remains relatively undervalued. InnoCare now stands at a “triple inflection point,” with profitability achieved, globalization enhanced, and core pipelines progressed, marking a new stage in its development.
Self-sustaining growth
Its latest report shows InnoCare’s revenue last year rose 135% to 2.38 billion yuan ($344 million). More importantly, it recorded an annual profit of about 644 million yuan, representing a swing of more than 1 billion yuan from its loss of 453 million yuan in 2024. The inflection point was notable as it was achieved two years ahead of the company’s original forecast, demonstrating its transition into a self-sustaining entity no longer reliant on external financing.
InnoCare also differs from some of its peers that achieved early profitability by relying on one-time upfront payments from partnerships. By comparison, InnoCare’s march to profitability has been jointly propelled by a dual engine of licensing deals and direct product sales. On the commercial front, the company’s drug sales reached 1.44 billion yuan last year, up 43.4%.
InnoCare’s profit breakthrough owes to two main factors: continued revenue growth driven by expanding indications for its main revenue engine Orelabrutinib, and significant cash inflows from licensing agreements with partners such as Zenas BioPharma (ZBIO.US). …